Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Psoriasis: Update Bulletin [October 2015]

Product Code:
596200520
Publication Date:
October 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events that have the potential to shape the treatment of plaque psoriasis. Topics covered include opinions on Pfizer’s Xeljanz (tofacitinib), and if it has a future as a treatment for psoriasis; Celgene’s Otezla (apremilast), and how new data from the Phase III LIBERATE study could provide clarity in terms of where Otezla might be positioned in the marketplace; new data for Novartis’ Cosentyx (secukinumab), including PASI 90 data and how this could drive product adoption; the future of AstraZeneca’s/Valeant’s brodalumab, and what further clinical development needs to be done to provide more clarity on the product’s depression/suicide risk; Boehringer Ingelheim’s BI 655066, including insight on what late-stage clinical studies will need to focus on; how KOLs believe the entrance of biosimilar versions of anti-TNF mAbs and fusion proteins will impact prescribing habits in the treatment of psoriasis, and what specific concerns do KOLs have about using biosimilars with their patients?

Key Questions Answered in this Update Bulletin:

  • Based on the US FDA’s Complete Response Letter (CRL) in response to Pfizer’s application to market Xeljanz (tofacitinib) for psoriasis, do the KOLs believe the drug will eventually gain approval, and if so, where in the treatment paradigm will it be used?
  • Do KOLs believe that new data for Celgene’s Otezla (apremilast), from the Phase III LIBERATE study, provides more clarity in terms of where Otezla might be positioned in the marketplace?
  • In the ongoing battle between Johnson & Johnson’s Stelara (ustekinumab) and Novartis’ Cosentyx (secukinumab), has recent data PASI 90 data from Novartis done anything to change KOL minds on which product is better for their patients?
  • What future does AstraZeneca’s/Valeant’s brodalumab have as a treatment for psoriasis, and do KOLs believe that further clinical development will provide any more clarity on the product’s depression/suicide risk?
  • How did KOLs respond to new Phase II data on Boehringer Ingelheim’s BI 655066, and what additional information is needed to prove safety and efficacy of the product?
  • How do KOLs believe the entrance of biosimilar versions of anti-TNF mAbs and fusion proteins will impact prescribing habits in the treatment of psoriasis, and what specific concerns do KOLs have about using biosimilars with their patients?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved